Moderna: launches clinical trial in collaboration with Merck

(CercleFinance.com) - Merck and Moderna have announced the launch of a pivotal Phase 3 clinical trial evaluating individual neoantigen therapy V940 (mRNA-4157) in combination with Keytruda.


The trial involves patients with operable stage II, IIIA or IIIB (N2) non-small cell lung cancer (NSCLC) who have failed to achieve a complete pathological response after neoadjuvant treatment with Keytruda and platinum-based chemotherapy.

Global recruitment has begun, with the first patients enrolling in Canada.

Kyle Holen, Senior Vice President at Moderna, said she is "excited" about this collaboration to improve outcomes for NSCLC patients through mRNA technology.

In addition, Merck and Moderna have initiated further Phase 3 clinical trials evaluating mRNA-4157 (V940) in combination with Keytruda for other cancer types, such as melanoma and cutaneous squamous cell carcinoma.


Copyright (c) 2024 CercleFinance.com. All rights reserved.